专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008082651A2 DUAL-SPECIFIC IL-1A/ IL-1B ANTIBODIES 审中-公开
标题翻译：双特异性IL-1A / IL-1B抗体
公开(公告)号：WO2008082651A2
公开(公告)日：2008-07-10
申请号：PCT/US2007026482
申请日：2007-12-28
申请人： ABBOTT LAB , HSIEH CHUNG-MING , MCRAE BRADFORD L , KUTSKOVA YULIYA , MEMMOTT JOHN E , ROGUSKA MICHAEL , TOMLINSON IAN , TUNA MIHRIBAN , GRANT STEVEN , ENEVER CARRIE
发明人： HSIEH CHUNG-MING , MCRAE BRADFORD L , KUTSKOVA YULIYA , MEMMOTT JOHN E , ROGUSKA MICHAEL , TOMLINSON IAN , TUNA MIHRIBAN , GRANT STEVEN , ENEVER CARRIE
IPC分类号： C07K16/24
CPC分类号： C07K16/468 , A61K39/3955 , A61K45/06 , C07K16/245 , C07K2317/569 , C07K2317/92
摘要： The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-l a and human IL-I ß. The dual specific antibodies of the invention also neutralize both human IL-I a and human IC-I ß. The invention also provides domain antibodies (dAbs) specific for human IL-l a and human IL-l ß.
摘要翻译：本发明提供了对人IL-1α和人IL-1β特异的分离的双重特异性抗体或其抗原结合部分。本发明的双重特异性抗体还中和人IL-1α和人IC-1β。本发明还提供对人IL-1α和人IL-1β特异性的结构域抗体（dAb）。

2. 发明申请

WO2009058383A3 LIGAND 审中-公开
标题翻译：配体
公开(公告)号：WO2009058383A3
公开(公告)日：2009-12-30
申请号：PCT/US2008012404
申请日：2008-10-31
申请人： DOMANTIS LTD , GRANT STEVEN , BASRAN AMRIK , IGNATOVICH OLGA , DE WILDT RUDOLPH MARIA T , JONES PHILIP , BREWIS NEIL , WOOLVEN BEN , DEANGELIS ELENA , HOLT LUCY J , WINTER GREG , TOMLINSON IAN , MOULDER KEVIN
发明人： GRANT STEVEN , BASRAN AMRIK , IGNATOVICH OLGA , DE WILDT RUDOLPH MARIA T , JONES PHILIP , BREWIS NEIL , WOOLVEN BEN , DEANGELIS ELENA , HOLT LUCY J , WINTER GREG , TOMLINSON IAN , MOULDER KEVIN
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/468 , A61K47/60 , A61K2039/505 , C07K14/415 , C07K16/18 , C07K16/22 , C07K16/241 , C07K16/2866 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2319/00
摘要： The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target.
摘要翻译：本发明提供了一种双特异性配体，其包含第一和第二单个可变结构域，各自具有针对抗原靶标的结合特异性。本发明还提供了特异性结合抗原靶标的单个可变结构域单体配体。

3. 发明申请

WO2010007376A3 COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE 审中-公开
标题翻译： CD28结合的组合物单一使用方法和使用方法
公开(公告)号：WO2010007376A3
公开(公告)日：2010-05-27
申请号：PCT/GB2009001762
申请日：2009-07-17
申请人： DOMANTIS LTD , ENEVER CAROLYN , GRANT STEVEN , SANSOM DAVID , HOLMES STEVE
发明人： ENEVER CAROLYN , GRANT STEVEN , SANSOM DAVID , HOLMES STEVE
IPC分类号： C07K16/28 , A61K39/395 , A61P37/06
CPC分类号： C07K16/2818 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76
摘要： The disclosure relates to a monovalent polypeptide domain which specifically binds CD28, as well as to an antagonist of CD28, where the antagonist comprises a monovalent polypeptide domain which specifically binds CD28. This disclosure encompasses monovalent polypeptide domains comprising an antibody single variable domain that monovalently binds CD28. An antibody single variable domain that is monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a monovalent anti-CD28 antibody single variable domain consists of or comprises an antibody single variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the monovalent anti-CD28 antibody single variable domain is a human antibody single variable domain. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a monovalent anti-CD28 antibody single variable domain to the individual.
摘要翻译：本公开涉及特异性结合CD28的单价多肽结构域以及CD28拮抗剂，其中拮抗剂包含特异性结合CD28的单价多肽结构域。本公开内容涵盖包含单价结合CD28的抗体单可变结构域的单价多肽结构域。用于结合CD28的单价抗体单可变区可抑制CD28活性。在一个方面，单价抗CD28抗体单可变结构域由一个方面组成或包含特异性结合和拮抗CD28的活性的抗体单可变结构域，而不具有实质上激动的CD28活性。另一方面，单价抗CD28抗体单可变结构域是人抗体单可变结构域。本公开还包括在个体中拮抗CD80和/或CD86相互作用的方法以及涉及CD80和/或CD86与CD28相互作用的疾病或病症的方法，涉及向单克隆抗CD28抗体单可变结构域施用的方法个人。

4. 发明申请

WO2008091620A3 COMBINATION THERAPY COMPRISING ROMIDEPSIN AND I.A. BORTEZOMIB 审中-公开
标题翻译：组合治疗包括ROMIDEPSIN和I.A. 硼替佐米
公开(公告)号：WO2008091620A3
公开(公告)日：2008-09-18
申请号：PCT/US2008000850
申请日：2008-01-23
申请人： GLOUCESTER PHARMACEUTICALS , KEEGAN MITCHELL , GRANT STEVEN
发明人： KEEGAN MITCHELL , GRANT STEVEN
IPC分类号： A61K31/69 , A61K38/15 , A61K45/06 , A61P35/00
CPC分类号： A61K38/07 , A61K31/69 , A61K38/15 , A61K45/06 , A61K2300/00
摘要： The invention provides a combination therapy for treating cancer and other neoplams including romidepsin and a proteasome inhibitor. When administered together, romidepsin and a proteasome inhibitor (e.g., bortezomib) interact synergistically to selectively kill malignant cells at low (nanomolar) concentrations. The effect is particularly pronounced in malignant hematological cells (e.g., leukemia, lymphoma, multiple myeloma). The combination has also been found useful in treating bortezomib-resistant cancers and steroid-resistant cancers. The invention provides methods of killing malignant cells in vitro and in vivo. Pharmaceutical compositions, preparations, and kits including romidepsin and a proteasome inhibitor are also provided.
摘要翻译：本发明提供了用于治疗癌症和其它肿瘤的组合疗法，包括罗非曲
汀和蛋白酶体抑制剂。当一起施用时，罗非替克和蛋白酶体抑制剂（例如，硼替佐米）协同作用以选择性地以低（纳摩尔）浓度杀死恶性细胞。在恶性血液细胞（例如白血病，淋巴瘤，多发性骨髓瘤）中，该作用特别明显。已经发现该组合可用于治疗硼替佐米耐药性癌症和类固醇抗性癌症。本发明提供在体外和体内杀死恶性细胞的方法。还提供了药物组合物，制剂和试剂盒，包括罗维切蛋白酶和蛋白酶体抑制剂。

5. 发明申请

WO2006030220A9 COMPOSITIONS MONOVALENT FOR CD40L BINDING AND METHODS OF USE 审中-公开
标题翻译： CD40L结合物的组合物单一使用方法和使用方法
公开(公告)号：WO2006030220A9
公开(公告)日：2006-10-19
申请号：PCT/GB2005003562
申请日：2005-09-16
申请人： DOMANTIS LTD , GRANT STEVEN , LIU HAIQUN , MOULDER KEVIN
发明人： GRANT STEVEN , LIU HAIQUN , MOULDER KEVIN
IPC分类号： C07K16/28 , A61K39/395 , A61P37/06
CPC分类号： C07K16/2875 , C07K2317/565 , C07K2317/569 , C07K2317/76
摘要： The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
摘要翻译：本发明涉及单价结合CD40L的抗体多肽。针对CD40L结合的单价抗体多肽可以抑制CD40L活性，同时避免可能与能够进行CD40L二价或多价结合的抗体发生的不良反应。一方面，单价抗CD40L抗体多肽由特异性结合和拮抗CD40L的活性的单个免疫球蛋白可变区组成或包含，优选不具有实质上激动的CD40和/或CD40L活性。另一方面，单价抗CD40L抗体多肽是人抗体多肽。本发明还包括拮抗个体中CD40 / CD40L相互作用的拮抗作用的方法以及治疗涉及CD40 / CD40L相互作用的疾病或病症的方法，涉及向个体施用单价抗CD40L抗体多肽的方法。

6. 发明申请

WO2006003388A8 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS 审中-公开
标题翻译：用于治疗炎症性疾病的组合物和方法
公开(公告)号：WO2006003388A8
公开(公告)日：2007-06-21
申请号：PCT/GB2005002553
申请日：2005-06-29
申请人： DOMANTIS LTD , IGNATOVICH OLGA , DE WILDT RUDOLF , WOOLVEN BENJAMIN , GRANT STEVEN , JONES PHILIP , BASRAN AMRIK , BREWIS NEIL
发明人： IGNATOVICH OLGA , DE WILDT RUDOLF , WOOLVEN BENJAMIN , GRANT STEVEN , JONES PHILIP , BASRAN AMRIK , BREWIS NEIL
IPC分类号： C07K16/24 , A61K39/395 , A61P19/02 , C07K16/22
CPC分类号： C07K16/22 , A61K47/60 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/241 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2317/626 , C07K2317/92 , C07K2319/00
摘要： The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.
摘要翻译：本发明涉及用于治疗炎症性疾病的组合物和方法。更具体地，本发明涉及抗体组合物及其在治疗炎症性疾病中的用途。

7. 发明申请

WO2006003388A3 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS 审中-公开
标题翻译：组合物和治疗炎性疾病的方法
公开(公告)号：WO2006003388A3
公开(公告)日：2006-04-27
申请号：PCT/GB2005002553
申请日：2005-06-29
申请人： DOMANTIS LTD , IGNATOVICH OLGA , DE WILDT RUDOLF , WOOLVEN BENJAMIN , GRANT STEVEN , JONES PHILIP , BASRAN AMRIK , BREWIS NEIL
发明人： IGNATOVICH OLGA , DE WILDT RUDOLF , WOOLVEN BENJAMIN , GRANT STEVEN , JONES PHILIP , BASRAN AMRIK , BREWIS NEIL
IPC分类号： C07K16/24 , A61K39/395 , A61P19/02 , C07K16/22
CPC分类号： C07K16/22 , A61K47/60 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/241 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2317/626 , C07K2317/92 , C07K2319/00
摘要： The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.
摘要翻译：本发明涉及用于治疗炎性疾病的组合物和方法。更具体地说，本发明涉及抗体组合物及其在炎症疾病治疗中的用途。

8. 发明申请

WO2004060269A3 MDA-7 AND FREE RADICALS IN THE TREATMENT OF CANCER 审中-公开
标题翻译： MDA-7和自由基在治疗癌症中的作用
公开(公告)号：WO2004060269A3
公开(公告)日：2004-10-14
申请号：PCT/US0328512
申请日：2003-09-09
申请人： UNIV COLUMBIA , UNIV VIRGINIA COMMONWEALTH , FISHER PAUL B , GOPALKRISHNAN RAHUL , LEBEDEVA IRINA , GRANT STEVEN , YACOUB ADLY , DENT PAUL
发明人： FISHER PAUL B , GOPALKRISHNAN RAHUL , LEBEDEVA IRINA , GRANT STEVEN , YACOUB ADLY , DENT PAUL
IPC分类号： A61K38/17 , A61K48/00 , C07K14/47 , C12N15/861 , A01N37/18 , A01N43/04 , C07H21/04 , C07K1/00 , C12N15/00 , C12N15/63
CPC分类号： C12N15/86 , A61K38/1709 , A61K48/00 , C07K14/47 , C07K2319/23 , C12N2710/10343 , C12N2810/00
摘要： The present invention relates to methods of treating a cancer in a subject comprising generating within one or more cancer cells of a subject an effective amount of MDA-7 and an effective amount of one or more free radicals. The present invention further relates to methods of inhibiting proliferation or promoting death in a cancer cell of a subject comprising generating within one or more cancer cells of a subject an effective amount of MDA-7 and an effective amount of one or more free radicals. Generation of an effective amount of MDA-7 can occur by administering to the cancer cell an effective amount of an mda-7 nucleic acid, MDA-7 protein, functional equivalents of either of these molecules, by upregulation of the endogenous mda-7 gene, or by stabilization of the mda-7 mRNA. Generation of one or more free radicals in a cancer cell can occur by exposing the cancer cell to an effective amount of ionizing radiation, a free radical, a generator of a free radical, a ROS, a generator of a ROS, or a disruptor of mitochondrial membrane potential.
摘要翻译：本发明涉及治疗受试者的癌症的方法，其包括在受试者的一个或多个癌细胞内产生有效量的MDA-7和有效量的一种或多种自由基。本发明进一步涉及抑制受试者癌细胞增殖或促进死亡的方法，包括在受试者的一个或多个癌细胞内产生有效量的MDA-7和有效量的一种或多种自由基。通过向癌细胞施用有效量的mda-7核酸，MDA-7蛋白，这些分子中的任一个的功能等价物，通过上调内源性mda-7基因，可以产生有效量的MDA-7 ，或通过稳定mda-7 mRNA。通过将癌细胞暴露于有效量的电离辐射，自由基，自由基的生成物，ROS，ROS的生成物或干扰物的干扰物，可以发生癌细胞中的一种或多种自由基线粒体膜电位。

9. 发明申请

WO2006097689A2 ANTIBODIES 审中-公开
标题翻译：抗体
公开(公告)号：WO2006097689A2
公开(公告)日：2006-09-21
申请号：PCT/GB2006000843
申请日：2006-03-10
申请人： DOMANTIS LTD , CASSONE ANTONIO , DE BERNARDIS FLAVIA , GRANT STEVEN , LIU HAIQUN
发明人： CASSONE ANTONIO , DE BERNARDIS FLAVIA , GRANT STEVEN , LIU HAIQUN
IPC分类号： C07K16/40 , A61K39/395 , A61P31/10
CPC分类号： C07K16/14 , A61K2039/505 , A61K2039/54 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/569 , C07K2317/76
摘要： This invention relates to domain antibodies. In particular, it relates to domain antibodies (dAbs) that recognize virulence traits of Candida spp. and confer passive protection against candidiasis.
摘要翻译：本发明涉及结构域抗体。特别涉及识别假丝酵母属的毒力性状的结构域抗体（dAb）。并给予针对念珠菌病的被动保护。

10. 发明申请

WO0226236A9 TUMOR CELL KILLING BY CELL CYCLE CHECKPOINT ABROGATION COMBINED WITH INHIBITION OF THE "CLASSICAL" MITOGEN ACTIVATED PROTEIN (MAP) KINASE PATHWAY 审中-公开
标题翻译：肿瘤细胞死亡细胞周期检查点组合抑制“经典”激素启动蛋白（MAP）激酶途径
公开(公告)号：WO0226236A9
公开(公告)日：2003-02-20
申请号：PCT/US0130508
申请日：2001-09-28
申请人： UNIV VIRGINIA COMMONWEALTH , DENT PAUL , GRANT STEVEN , MCKINSTRY ROBERT , DAI YUM
发明人： DENT PAUL , GRANT STEVEN , MCKINSTRY ROBERT , DAI YUM
IPC分类号： A61K31/52 , A61K31/522 , A61K31/535 , A61K31/55 , A61K41/00 , A01N43/02 , A61K31/335
CPC分类号： A61K41/00 , A61K31/52 , A61K31/522 , A61K31/535 , A61K31/55 , A61K31/365 , A61K31/35 , A61K31/275 , A61K31/165 , A61K2300/00
摘要： The present invention provides a method for treating cancer by promoting apoptosis and reducing clonogenic survival of cancer cells. The method encompasses co-administering 1) a cell cycle checkpoint abrogation agent (for example, UCN-01 or caffeine) and 2) an inhibitor of a compensatory cytoprotective pathway, such as an agent that inhibits the MEK 1/2 pathway (e.g. PD98059, U0126, or PD184352) or an agent that inhibits the PI 3 pathway (e.g. LY294002 or wortmanin). In addition, because the co-administration step also radiosensitizes cancer cells, the method additionally encompasses the administration of radiation to further reduce clonogenic survival of cancer cells. The method promotes apoptosis and reduces clonogenic survival in many types of cancer cells, including leukemia cells, prostate cancer cells, breast cancer cells, myeloma cells, and lymphoma cells.
摘要翻译：本发明提供了通过促进细胞凋亡和降低癌细胞的克隆生存来治疗癌症的方法。该方法包括共同施用1）细胞周期检查点废除剂（例如UCN-01或咖啡因）和2）补偿性细胞保护途径的抑制剂，例如抑制MEK 1/2途径的试剂（例如PD98059 ，U0126或PD184352）或抑制PI3途径的试剂（例如LY294002或wortmanin）。此外，由于共同给药步骤也对癌细胞进行放射增敏，该方法另外包括辐射的施用以进一步降低癌细胞的克隆形成存活。该方法促进许多类型的癌细胞（包括白血病细胞，前列腺癌细胞，乳腺癌细胞，骨髓瘤细胞和淋巴瘤细胞）中的细胞凋亡和降低克隆生存。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式